DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 211 filers reported holding DENALI THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 4.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $643,264 | -29.0% | 31,181 | +1.5% | 0.01% | -28.6% |
| Q2 2023 | $906,311 | +42.8% | 30,712 | +11.5% | 0.01% | +16.7% |
| Q1 2023 | $634,660 | -6.3% | 27,546 | +13.1% | 0.01% | -14.3% |
| Q4 2022 | $677,563 | -5.6% | 24,364 | +4.2% | 0.01% | 0.0% |
| Q3 2022 | $718,000 | +5.3% | 23,388 | +1.0% | 0.01% | 0.0% |
| Q2 2022 | $682,000 | -1.2% | 23,167 | +8.0% | 0.01% | +16.7% |
| Q1 2022 | $690,000 | -27.3% | 21,458 | +0.8% | 0.01% | -14.3% |
| Q4 2021 | $949,000 | -12.4% | 21,280 | -0.8% | 0.01% | -22.2% |
| Q3 2021 | $1,083,000 | -34.8% | 21,458 | +1.3% | 0.01% | -35.7% |
| Q2 2021 | $1,662,000 | +28.2% | 21,188 | -6.6% | 0.01% | +27.3% |
| Q1 2021 | $1,296,000 | -31.0% | 22,690 | +1.2% | 0.01% | -35.3% |
| Q4 2020 | $1,878,000 | +119.4% | 22,420 | -6.2% | 0.02% | +88.9% |
| Q3 2020 | $856,000 | +98.1% | 23,904 | +33.9% | 0.01% | +50.0% |
| Q2 2020 | $432,000 | +68.1% | 17,846 | +21.8% | 0.01% | +50.0% |
| Q1 2020 | $257,000 | – | 14,654 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |